5 questions facing emerging biotech in 2025
Healthcare dealmakers eye M&A resurgence in second Trump term
Reduced dosing and expanded manufacturing paving way for Amgen’s obesity entrance
Merck is broadening its pipeline as Keytruda’s patent cliff looms
*please scroll down for all the latest news*